Fineline Cube

Follow:
14398 Articles
AstraZeneca's Zoladex Receives NMPA Approval for Higher Dosage Form in Breast Cancer Treatment
CompanyDrug

AstraZeneca’s Zoladex Receives NMPA Approval for Higher Dosage Form in Breast Cancer Treatment

"MicuRx Pharmaceuticals' Antibiotic MRX-5 Completes Successful Phase I Clinical Trial in Australia
CompanyDrug

MicuRx Pharmaceuticals’ Antibiotic MRX-5 Completes Successful Phase I Clinical Trial in Australia

NMPA's CDE Prioritizes Marketing Filings for Innovative Drugs with Priority Review Status
Policy / Regulatory

NMPA’s CDE Prioritizes Marketing Filings for Innovative Drugs with Priority Review Status

Wantai Biological's P85 Ab Detection Kit Receives NMPA Approval for Nasopharyngeal Carcinoma Screening
CompanyMedical Device

Wantai Biological’s P85 Ab Detection Kit Receives NMPA Approval for Nasopharyngeal Carcinoma Screening

Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China
CompanyDrug

Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China

GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania
CompanyDeals

GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania

ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development
CompanyDeals

ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development

LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
CompanyDeals

LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS

Zhuhai Beihai Biotech's Beizary Receives FDA Clearance for Multiple Cancer Indications
CompanyDrug

Zhuhai Beihai Biotech’s Beizary Receives FDA Clearance for Multiple Cancer Indications

BeiGene's PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option
CompanyDrug

BeiGene’s PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option

RemeGen's Telitacicept Receives Priority Review Status from China's CDE for gMG Treatment
CompanyDrug

RemeGen’s Telitacicept Receives Priority Review Status from China’s CDE for gMG Treatment

China's Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports
Policy / Regulatory

China’s Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports